Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talimogene laherparepvec plus ipilimumab versus ipilimumab alone in unresected stage IIIB–IV melanoma
2012-000307-32Phase 2Completed
- Sponsor
- Amgen
- Start
- May 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in melanoma comparing Talimogene laherparepvec + ipilimumab with Ipilimumab alone (2 arms). Primary endpoint: Dose-limiting toxicities (DLT) in phase 1b. Started May 2014; status: completed.
02
Drugs
talimogene laherparepvecipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2012-000307-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000307-32.